A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamic (PD) Effects of Posiphen® in Subjects With Early Alzheimer's Disease (AD)
Phase of Trial: Phase I/II
Latest Information Update: 06 Apr 2018
At a glance
- Drugs R-phenserine (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Acronyms DISCOVER
- Sponsors QR Pharma
- 27 Feb 2018 Planned End Date changed from 1 Dec 2018 to 31 Dec 2019.
- 27 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 31 Dec 2019.
- 10 Jun 2017 Biomarkers information updated